Back to Search
Start Over
Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- PDF file - 70KB, Supplementary Table 2. Grade 3/4 Adverse Events that Occurred in ≥2% of Patients.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....a3892ccb08f5e55c4373b2f701e87fbf
- Full Text :
- https://doi.org/10.1158/1078-0432.22448583.v1